DermaSensor, Inc.
This randomized controlled trial evaluates whether primary care physician access to the DermaSensor device increases the proportion of patients with histopathology-confirmed skin cancer compared with physician standard clinical assessment alone. Participating physicians are randomized and outcomes are drawn from existing electronic health record data for up to 500,000 patient encounters.
Inclusion Criteria: * Practicing primary care provider in the labeled user population for the DermaSensor device (per the Instructions for Use) * Practicing at a participating site that uses an EMR system modifiable at the user level * Practicing at a participating site that routinely documents skin check data, including coding for skin checks and lesion diagnoses * Practicing at a participating site where pathology results for patients referred to dermatology are routinely accessible for study analyses Exclusion Criteria: \- Not actively practicing in primary care at a participating study…
Handheld device used by primary care physicians as an adjunct to clinical assessment of skin lesions suggestive of skin cancer, per its labeling.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.